EP2944309A1 - Verwendung von palmitoylethanolamid in kombination mit opioiden - Google Patents

Verwendung von palmitoylethanolamid in kombination mit opioiden Download PDF

Info

Publication number
EP2944309A1
EP2944309A1 EP15166284.8A EP15166284A EP2944309A1 EP 2944309 A1 EP2944309 A1 EP 2944309A1 EP 15166284 A EP15166284 A EP 15166284A EP 2944309 A1 EP2944309 A1 EP 2944309A1
Authority
EP
European Patent Office
Prior art keywords
palmitoylethanolamide
opioid
use according
treatment
pea
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP15166284.8A
Other languages
English (en)
French (fr)
Other versions
EP2944309B1 (de
Inventor
Francesco Della Valle
Maria Federica Della Valle
Lorenzo Di Cesare Manelli
Carla Ghelardini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epitech Group SpA
Original Assignee
Epitech Group SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epitech Group SpA filed Critical Epitech Group SpA
Priority to PL15166284T priority Critical patent/PL2944309T3/pl
Publication of EP2944309A1 publication Critical patent/EP2944309A1/de
Application granted granted Critical
Publication of EP2944309B1 publication Critical patent/EP2944309B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

  • This invention relates to a pharmaceutical composition for human or animal use containing N-palmitoylethanolamide as an analgesic in combination with opioids.
  • Opioids are substances active on the opioid receptor and having an analgesic action. They include both natural alkaloids such as morphine and its analogues (also called opiates, since derived from opium) and synthetic or semi-synthetic compounds with an alkaloid (heroin) or non-alkaloid (methadone) structure.
  • Morphine the principal natural alkaloid extracted from Papaver somniferum, is the therapeutic treatment of choice for the control of moderate and severe pain.
  • the application of the substance in the continuous therapy of persistent pain is limited by the development of tolerance to the analgesic effect.
  • the development of tolerance requires continuous dose increases to achieve the same analgesic effect. This complex pathophysiological cycle helps to decrease the quality of life of patients due to excessive sedation, reduced physical activity, constipation, respiratory depression, etc.
  • Palmitoylethanolamide is an endogenous amide formed from palmitic acid and ethanolamine. It is a lipidic mediator known to exert antinociceptive effects against different types of pain and is characterized by an interesting antineuropathic profile, especially when used in a micronized or ultra-micronized form.
  • PEA has the ability to significantly reduce the activation of glial cells in the spinal cord and brain in pathologies characterized by chronic pain.
  • ultra-micronized PEA is able to intervene in the processes of development of tolerance due to the prolonged use of opioids, in particular morphine.
  • the association of PEA to the opioid allows prolonging the efficacy of the treatment providing a duration of the analgesic effect that is double compared to treatment with the opioid administered alone.
  • An object of this invention is thus palmitoylethanolamide (PEA), alternately in non-micronized form (non-micronized PEA), in micronized form (PEA-m) or in ultra-micronized form (PEA-um), for use in combination with an opioid in the treatment of pain conditions, wherein said palmitoylethanolamide is administered separately, sequentially, or in combination with said opioid.
  • PDA palmitoylethanolamide
  • the object of this invention is palmitoylethanolamide (PEA), alternately in non-micronized form (non-micronized PEA), in micronized form (PEA-m) or in ultra-micronized form (PEA-um), or a pharmaceutical composition that includes it, for use in a patient as an analgesic in combination with an opioid, wherein said palmitoylethanolamide retards the development of tolerance to the opioid in the patient.
  • PDA palmitoylethanolamide
  • Figure 1 shows a graph relating to a "paw pressure" test on rats using morphine alone or morphine in combination with PEA.
  • the invention relates to palmitoylethanolamide (PEA), alternatively in non-micronized form (non-micronized PEA), in micronized form (PEA-m), in ultra-micronized form (PEA-um) or mixtures thereof, for use in humans or animals in combination with an opioid in the treatment of pain conditions, wherein said palmitoylethanolamide is administered separately, sequentially, or in combination with said opioid.
  • PDA palmitoylethanolamide
  • the invention relates to palmitoylethanolamide (PEA), alternately in non-micronized form (non-micronized PEA), in micronized form (PEA-m), in ultra-micronized form (PEA-um), mixtures thereof, or a pharmaceutical composition that includes it, for use in a patient as an analgesic in combination with an opioid, wherein said palmitoylethanolamide retards the development of tolerance to the opioid in the patient.
  • PDA palmitoylethanolamide
  • Palmitoylethanolamide can be synthesized as described in example no. 25 of patent US 5,990,170 .
  • Non-micronized PEA can be obtained by finely grinding the product obtained from synthesis; one can obtain a product with particle size between 50.0 and 100.0 ⁇ m.
  • PEA-m can be obtained as described in patent US 6,548,550 B1 and has a particle size of between 2.0 and 10.0 ⁇ m.
  • PEA-um can be obtained as described in PCT application no. WO 2011/027373 A1 and has a particle size of between 0.8 and 6.0 ⁇ m.
  • the opioid is selected from natural alkaloids, also called opiates or compounds of synthesis or semi-synthesis.
  • the opioid is selected from: Morphine, Heroin, Etorphine, Hydromorphone, Oxymorphone, Levorphanol, Codeine, Hydrocodone, Oxycodone, Nalmefene, Nalorphine, Naloxone, Naltrexone, Buprenorphine, Butorphanol, Nalbuphine, Methylnaltrexone, Fentanyl and Methadone.
  • the opioid is morphine.
  • the opioids can be administered in humans by means of the various traditional routes of administration in accordance with the instructions contained in Goodman and Gilman's "The Pharmacological Basis of Therapeutics" 12th edition - Chapter 18, Table 18-2, page 498 .
  • Palmitoylethanolamide can be administered in humans starting from 1 day before the start of the treatment with the opioid, or if necessary, by carrying out a 10-day pre-treatment before the start of treatment with the opioid.
  • Palmitoylethanolamide is between 3 and 50 mg/kg of patient weight (preferably 20-30 mg/kg) preferably divided into two daily treatments spaced 8-10 hours apart.
  • the daily treatment with palmitoylethanolamide has to be maintained during the entire period of treatment with the opioid. It must be considered that it may be necessary to make continuous changes in the dosage depending on the age and weight of the patient and even the severity of the medical condition being treated. The exact dose and route of administration will ultimately be at the discretion of the attending physician or veterinarian.
  • the treatment with palmitoylethanolamide is administered orally, sublingually or rectally in the pharmaceutical forms of tablets, hard gelatine capsules, soft gelatine capsules in an oily vehicle, granulate for sublingual use, emulsion for oral use, effervescent tablets, suppositories, or microenemas.
  • the inventive composition may thus contain pharmaceutically acceptable excipients and additives, selected as a function of the pharmaceutical form chosen.
  • the pharmaceutical compositions may contain pharmaceutically acceptable excipients such as binding agents (for example pregelatinised corn starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); filling agents (for example lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (for example magnesium stearate, talc or silica); disintegrants (for example potato starch or sodium starch glycolate); or inhibiting agents (for example sodium lauryl sulphate).
  • binding agents for example pregelatinised corn starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose
  • filling agents for example lactose, microcrystalline cellulose or calcium hydrogen phosphate
  • lubricants for example magnesium stearate, talc or silica
  • disintegrants for example potato starch or sodium starch glycolate
  • inhibiting agents for example sodium lauryl sulphate.
  • the tablets may be coated by methods well known in the art.
  • the liquid preparations for oral administration can
  • Such liquid preparations may be prepared by conventional methods with pharmaceutically acceptable additives such as suspending agents (for example sorbitol syrup, cellulose derivatives or edible hydrogenated fats); emulsifying agents (for example lecithin or acacia); non-aqueous vehicles (for example almond oil, oily esters, ethyl alcohol or fractionated vegetable oils); and preservatives (for example methyl- or propyl-p-hydroxybenzoates or sorbic acid).
  • suspending agents for example sorbitol syrup, cellulose derivatives or edible hydrogenated fats
  • emulsifying agents for example lecithin or acacia
  • non-aqueous vehicles for example almond oil, oily esters, ethyl alcohol or fractionated vegetable oils
  • preservatives for example methyl- or propyl-p-hydroxybenzoates or sorbic acid.
  • the preparation may also appropriately contain flavourings, colourings and sweetening agents.
  • the preparations for oral administration may be formulated in a manner suitable to allow the controlled release of the active ingredient.
  • compositions may be in the form of tablets or lozenges formulated in a conventional manner, suitable for absorption in the buccal mucosa.
  • Typical buccal formulations are tablets for sublingual administration.
  • the compounds may also be formulated according rectal compositions such as suppositories, retention enemas or micro-enemas, for example containing the basic components of common suppositories such as cocoa butter or other glycerides.
  • the compounds may also be formulated as deposit preparations.
  • Such long-acting formulations can be administered by implantation (for example in a subcutaneous, transcutaneous or intramuscular manner) or by intramuscular injection.
  • the compounds according to this invention can be formulated with suitable polymeric or hydrophobic materials (for example in the form of an emulsion in a suitable oil), ion exchange resins, or as minimally soluble derivatives such as, for example, minimally soluble salt.
  • formulations described above can be prepared according to conventional methods, such as those described in Remington's Pharmaceutical Sciences Handbook, Mack Pub. Co., NY, USA.
  • PEA-um ultra-micronized PEA suspended in the vehicle as indicated above. Starting from day 1, and then in the following days, morphine was administered (10 mg/kg i.p.). As shown in Figure 1 , the painful threshold was measured before injection of morphine (pretest) and 30 minutes after.
  • the behavioural assessments were made using the "Paw Pressure” test (Ugo Basile, Paw Pressure Analgesy Meter “Randar-Selitto” Rat) evaluating the weight supported by the animal on the hind leg.
  • the rats treated with vehicle + morphine showed a significant increase of the pain threshold compared to the pretest up to the 5th day of treatment, when they developed tolerance that did not allow the detection of further analgesic effects.
  • ultra-micronized PEA is able to intervene in the processes of development of tolerance due to the prolonged use of opioids, exemplified in the present model by morphine.
  • the association of PEA to the opioid allows prolonging the efficacy of the treatment providing a duration of the analgesic effect that is double compared to treatment with the opioid administered alone.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Dispersion Chemistry (AREA)
EP15166284.8A 2014-05-14 2015-05-04 Verwendung von palmitoylethanolamid in kombination mit opioiden Active EP2944309B1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL15166284T PL2944309T3 (pl) 2014-05-14 2015-05-04 Zastosowanie palmitoiloetanoloamidu w połączeniu z opioidami

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITMI20140876 2014-05-14

Publications (2)

Publication Number Publication Date
EP2944309A1 true EP2944309A1 (de) 2015-11-18
EP2944309B1 EP2944309B1 (de) 2019-03-20

Family

ID=51179022

Family Applications (1)

Application Number Title Priority Date Filing Date
EP15166284.8A Active EP2944309B1 (de) 2014-05-14 2015-05-04 Verwendung von palmitoylethanolamid in kombination mit opioiden

Country Status (16)

Country Link
US (1) US9801836B2 (de)
EP (1) EP2944309B1 (de)
JP (1) JP6563685B2 (de)
KR (1) KR102507891B1 (de)
CN (1) CN105079811B (de)
AR (1) AR100444A1 (de)
AU (1) AU2015202575B9 (de)
BR (1) BR102015011079A2 (de)
CA (1) CA2891049C (de)
CY (1) CY1121773T1 (de)
DK (1) DK2944309T3 (de)
ES (1) ES2731729T3 (de)
HU (1) HUE044915T2 (de)
PL (1) PL2944309T3 (de)
PT (1) PT2944309T (de)
TR (1) TR201908936T4 (de)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016185468A1 (en) * 2015-05-21 2016-11-24 Therapix Biosciences Ltd. Combinations of opioids and n-acylethanolamines
US10973782B2 (en) 2017-09-05 2021-04-13 Frimline Private Limited Pharmaceutical composition for improving or preventing progression of chronic kidney disease

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020141546A1 (en) 2019-01-02 2020-07-09 Celagenex Research (India) Pvt. Ltd. Synergistic nutritional compositions for pain management

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5990170A (en) 1994-12-14 1999-11-23 Lifegroup S.P.A. Therapeutic use of mono and bicarboxylic acid amides active at the peripheral cannabinoid receptor
US6548550B1 (en) 1999-08-06 2003-04-15 Innovet Italia S.R.L. Pharmaceutical compositions containing N-palmitoylethanolamide and use thereof in the veterinary field
WO2011027373A1 (en) 2009-09-07 2011-03-10 Epitech Group S.R.L. Composition containing ultra-micronized palmitoyl - ethanolamide

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE406867T1 (de) 2001-07-18 2008-09-15 Unilever Nv Zusammensetzungen für die behandlung von haaren und/oder kopfhaut
US20050245557A1 (en) * 2003-10-15 2005-11-03 Pain Therapeutics, Inc. Methods and materials useful for the treatment of arthritic conditions, inflammation associated with a chronic condition or chronic pain
EP2411382A1 (de) * 2009-03-27 2012-02-01 Abbott Laboratories Verbindungen als cannabinoidrezeptorliganden

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5990170A (en) 1994-12-14 1999-11-23 Lifegroup S.P.A. Therapeutic use of mono and bicarboxylic acid amides active at the peripheral cannabinoid receptor
US6548550B1 (en) 1999-08-06 2003-04-15 Innovet Italia S.R.L. Pharmaceutical compositions containing N-palmitoylethanolamide and use thereof in the veterinary field
WO2011027373A1 (en) 2009-09-07 2011-03-10 Epitech Group S.R.L. Composition containing ultra-micronized palmitoyl - ethanolamide

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DOMÍNGUEZ C MORERA ET AL: "N-palmitoylethanolamide in the treatment of neuropathic pain associated with lumbosciatica.", PAIN MANAGEMENT MAR 2012, vol. 2, no. 2, March 2012 (2012-03-01), pages 119 - 124, XP008174095, ISSN: 1758-1869 *
GATTI A ET AL: "Palmitoylethanolamide in the treatment of chronic pain caused by different etiopathogenesis", PAIN MEDICINE, BLACKWELL SCIENCE, MALDEN, US, vol. 13, no. 9, 1 September 2012 (2012-09-01), pages 1121 - 1130, XP002730844, ISSN: 1526-2375, [retrieved on 20120730], DOI: 10.1111/J.1526-4637.2012.01432.X *
GOODMAN; GILMAN: "The Pharmacological Basis of Therapeutics 12th edition", article "Chapter 18, Table 18-2", pages: 498
HALLER V L ET AL: "Non-cannabinoid CB1, non-cannabinoid CB2 antinociceptive effects of several novel compounds in the PPQ stretch test in mice", EUROPEAN JOURNAL OF PHARMACOLOGY, ELSEVIER SCIENCE, NL, vol. 546, no. 1-3, 28 September 2006 (2006-09-28), pages 60 - 68, XP028029180, ISSN: 0014-2999, [retrieved on 20060928], DOI: 10.1016/J.EJPHAR.2006.07.024 *
STEPHEN D. SKAPER ET AL: "Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain", INFLAMMOPHARMACOLOGY, vol. 22, no. 2, 1 November 2013 (2013-11-01), pages 79 - 94, XP055160931, ISSN: 0925-4692, DOI: 10.1007/s10787-013-0191-7 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016185468A1 (en) * 2015-05-21 2016-11-24 Therapix Biosciences Ltd. Combinations of opioids and n-acylethanolamines
AU2016263292B2 (en) * 2015-05-21 2021-04-01 Scisparc Ltd Combinations of opioids and N-acylethanolamines
US10973782B2 (en) 2017-09-05 2021-04-13 Frimline Private Limited Pharmaceutical composition for improving or preventing progression of chronic kidney disease

Also Published As

Publication number Publication date
US9801836B2 (en) 2017-10-31
AU2015202575B2 (en) 2020-03-05
CA2891049C (en) 2023-02-21
DK2944309T3 (da) 2019-06-03
US20150328173A1 (en) 2015-11-19
JP6563685B2 (ja) 2019-08-21
ES2731729T3 (es) 2019-11-18
EP2944309B1 (de) 2019-03-20
CY1121773T1 (el) 2020-07-31
CN105079811A (zh) 2015-11-25
KR20150130931A (ko) 2015-11-24
AR100444A1 (es) 2016-10-05
CN105079811B (zh) 2020-06-23
JP2015221794A (ja) 2015-12-10
TR201908936T4 (tr) 2019-07-22
PT2944309T (pt) 2019-06-05
BR102015011079A2 (pt) 2016-03-29
KR102507891B1 (ko) 2023-03-08
PL2944309T3 (pl) 2019-09-30
CA2891049A1 (en) 2015-11-14
HUE044915T2 (hu) 2019-11-28
AU2015202575B9 (en) 2020-03-26
AU2015202575A1 (en) 2015-12-03

Similar Documents

Publication Publication Date Title
JP6216305B2 (ja) 薬物過量摂取の治療のためのモルヒナン誘導体
US5256669A (en) Methods and compositions for treating acute or chronic pain and drug addiction
JP6010572B2 (ja) 嗜癖の予防および治療のための組成物および方法
KR950002746A (ko) 방출억제성 오피오이드 제형
TWI453020B (zh) 嗎啡喃衍生物或其藥理容許酸加成鹽之用以製造防止皮膚乾燥、改善肌膚粗糙、改善伴隨角質肥厚之發暗之改善治療藥之用途
EA013544B1 (ru) Применение оксикодона для лечения висцеральной боли
US9801836B2 (en) Using palmitoylethanolamide in combination with opioids
JPS6342605B2 (de)
RU2587329C2 (ru) Лекарственная комбинация с теобромином и ее использование в лечении
JP2014515405A (ja) オピオイド受容体アゴニストの逐次投与のための組成物
JP2014505113A (ja) 末梢作用性μオピオイドアンタゴニスト
KR20090125748A (ko) 대상포진 후 신경통 치료용 정제 및 대상포진 후 신경통의 치료 방법
CA2829280C (en) Compositions of opioid antagonists and their use for treating scleroderma
US20120252831A1 (en) Compositions of opioid antagonists and methods for treating scleroderma therewith
WO2008075997A1 (en) Method for treating opioid withdrawal syndrome
EP1620106A1 (de) Pharmazeutische zusammensetzung einen cathepsin s inhibitor und ein opioid enthaltend

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

17P Request for examination filed

Effective date: 20151202

RBV Designated contracting states (corrected)

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20180717

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/164 20060101AFI20181029BHEP

Ipc: A61K 31/4468 20060101ALI20181029BHEP

Ipc: A61K 45/06 20060101ALI20181029BHEP

Ipc: A61P 25/04 20060101ALI20181029BHEP

Ipc: A61K 9/14 20060101ALI20181029BHEP

Ipc: A61K 31/485 20060101ALI20181029BHEP

INTG Intention to grant announced

Effective date: 20181127

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

RIN1 Information on inventor provided before grant (corrected)

Inventor name: DI CESARE MANELLI, LORENZO

Inventor name: DELLA VALLE, FRANCESCO

Inventor name: DELLA VALLE, MARIA FEDERICA

Inventor name: GHELARDINI, CARLA

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602015026632

Country of ref document: DE

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1109795

Country of ref document: AT

Kind code of ref document: T

Effective date: 20190415

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: RO

Ref legal event code: EPE

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: VALIPAT S.A. C/O BOVARD SA NEUCHATEL, CH

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20190529

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Ref document number: 2944309

Country of ref document: PT

Date of ref document: 20190605

Kind code of ref document: T

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20190523

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: NO

Ref legal event code: T2

Effective date: 20190320

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190320

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20190401600

Country of ref document: GR

Effective date: 20190708

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190320

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190620

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190320

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190320

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190320

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190320

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190320

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190320

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2731729

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20191118

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E044915

Country of ref document: HU

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190720

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602015026632

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190320

26N No opposition filed

Effective date: 20200102

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190320

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 1109795

Country of ref document: AT

Kind code of ref document: T

Effective date: 20190320

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190320

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230523

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: RO

Payment date: 20240327

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20240305

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20240522

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20240527

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20240524

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20240521

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20240521

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 20240527

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20240523

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20240602

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20240603

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20240521

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SM

Payment date: 20240507

Year of fee payment: 10

Ref country code: NO

Payment date: 20240523

Year of fee payment: 10

Ref country code: FR

Payment date: 20240423

Year of fee payment: 10

Ref country code: FI

Payment date: 20240521

Year of fee payment: 10

Ref country code: CY

Payment date: 20240326

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PL

Payment date: 20240429

Year of fee payment: 10

Ref country code: PT

Payment date: 20240426

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20240501

Year of fee payment: 10

Ref country code: SE

Payment date: 20240516

Year of fee payment: 10

Ref country code: MT

Payment date: 20240424

Year of fee payment: 10

Ref country code: HU

Payment date: 20240523

Year of fee payment: 10

Ref country code: BE

Payment date: 20240521

Year of fee payment: 10